Icon (NASDAQ:ICLR) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.

A number of other research analysts also recently issued reports on ICLR. Mizuho set a $109.00 price target on Icon and gave the company a “hold” rating in a report on Wednesday, January 24th. SunTrust Banks restated a “buy” rating and set a $133.00 price target on shares of Icon in a report on Monday, January 22nd. Evercore ISI initiated coverage on Icon in a report on Thursday, January 18th. They set an “outperform” rating and a $126.00 price target on the stock. KeyCorp restated a “buy” rating and set a $130.00 price target on shares of Icon in a report on Thursday, January 11th. Finally, Zacks Investment Research downgraded Icon from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $124.55.

Shares of Icon (NASDAQ ICLR) opened at $107.02 on Friday. Icon has a 52 week low of $76.46 and a 52 week high of $124.48. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $5,795.35, a PE ratio of 20.54, a PEG ratio of 1.51 and a beta of 0.48.

Several hedge funds have recently bought and sold shares of ICLR. Koch Industries Inc. grew its holdings in shares of Icon by 17,508.8% during the 2nd quarter. Koch Industries Inc. now owns 666,140 shares of the medical research company’s stock worth $659,000 after acquiring an additional 662,357 shares during the period. Principal Financial Group Inc. grew its holdings in shares of Icon by 71.5% during the 3rd quarter. Principal Financial Group Inc. now owns 768,471 shares of the medical research company’s stock worth $87,513,000 after acquiring an additional 320,356 shares during the period. WCM Investment Management CA grew its holdings in shares of Icon by 5.8% during the 4th quarter. WCM Investment Management CA now owns 4,281,211 shares of the medical research company’s stock worth $480,138,000 after acquiring an additional 233,990 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Icon by 530.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 248,202 shares of the medical research company’s stock worth $28,265,000 after acquiring an additional 208,816 shares during the period. Finally, Westfield Capital Management Co. LP grew its holdings in shares of Icon by 12.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 869,018 shares of the medical research company’s stock worth $98,964,000 after acquiring an additional 94,345 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://theolympiareport.com/2018/02/11/icon-iclr-upgraded-by-bidaskclub-to-sell.html.

About Icon

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.